Creative Planning Has $334,000 Stock Holdings in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Creative Planning lifted its position in LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 20.7% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,594 shares of the medical instruments supplier’s stock after acquiring an additional 617 shares during the quarter. Creative Planning’s holdings in LeMaitre Vascular were worth $334,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in LMAT. Norden Group LLC bought a new stake in shares of LeMaitre Vascular in the 1st quarter worth $401,000. BNP Paribas Financial Markets grew its stake in shares of LeMaitre Vascular by 135.6% in the 1st quarter. BNP Paribas Financial Markets now owns 22,917 shares of the medical instruments supplier’s stock worth $1,521,000 after acquiring an additional 13,189 shares in the last quarter. Texas Permanent School Fund Corp grew its stake in shares of LeMaitre Vascular by 1.3% in the 1st quarter. Texas Permanent School Fund Corp now owns 17,341 shares of the medical instruments supplier’s stock worth $1,151,000 after acquiring an additional 225 shares in the last quarter. Envestnet Portfolio Solutions Inc. bought a new stake in shares of LeMaitre Vascular in the 1st quarter worth $206,000. Finally, Quantbot Technologies LP grew its stake in shares of LeMaitre Vascular by 1,001.4% in the 1st quarter. Quantbot Technologies LP now owns 7,335 shares of the medical instruments supplier’s stock worth $487,000 after acquiring an additional 6,669 shares in the last quarter. Institutional investors own 84.64% of the company’s stock.

LeMaitre Vascular Stock Up 3.1 %

Shares of NASDAQ:LMAT opened at $104.25 on Friday. The firm has a market capitalization of $2.34 billion, a PE ratio of 56.97, a P/E/G ratio of 2.49 and a beta of 0.89. LeMaitre Vascular, Inc. has a twelve month low of $47.72 and a twelve month high of $104.81. The company has a 50-day moving average price of $90.66 and a two-hundred day moving average price of $84.27.

LeMaitre Vascular (NASDAQ:LMAT) last announced its quarterly earnings results on Thursday, October 31st. The medical instruments supplier reported $0.49 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.44 by $0.05. LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.15%. The firm had revenue of $54.82 million for the quarter, compared to the consensus estimate of $53.50 million. During the same period in the prior year, the firm posted $0.33 earnings per share. The company’s revenue for the quarter was up 15.6% on a year-over-year basis. Analysts anticipate that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current fiscal year.

LeMaitre Vascular Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, December 5th. Investors of record on Thursday, November 21st will be paid a $0.16 dividend. This represents a $0.64 dividend on an annualized basis and a yield of 0.61%. The ex-dividend date is Thursday, November 21st. LeMaitre Vascular’s dividend payout ratio is currently 34.97%.

Insider Activity at LeMaitre Vascular

In related news, Director David B. Roberts sold 3,063 shares of the firm’s stock in a transaction that occurred on Tuesday, August 13th. The shares were sold at an average price of $82.07, for a total value of $251,380.41. Following the sale, the director now directly owns 14,114 shares of the company’s stock, valued at $1,158,335.98. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 10.79% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on LMAT. StockNews.com upgraded shares of LeMaitre Vascular from a “hold” rating to a “buy” rating in a research report on Wednesday. Oppenheimer restated an “outperform” rating and set a $93.00 price target (up previously from $90.00) on shares of LeMaitre Vascular in a research report on Friday, November 1st. Barrington Research increased their price target on shares of LeMaitre Vascular from $92.00 to $93.00 and gave the company an “outperform” rating in a research report on Friday, November 1st. Lake Street Capital began coverage on shares of LeMaitre Vascular in a research report on Friday, August 2nd. They set a “buy” rating and a $105.00 price target for the company. Finally, Cantor Fitzgerald began coverage on shares of LeMaitre Vascular in a research report on Tuesday, October 15th. They set a “neutral” rating and a $96.00 price target for the company. Two research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $94.57.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.